A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)
A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)
A Global Study to Assess the Effects of MEDI4736 following concurrent chemoradiation in Patients with Stage III Unresectable Non-Small Cell Lung Cancer.
A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)
Inclusion Criteria:
Exclusion Criteria:
Libramont-Chevigny, 6800, Belgium
Habikino-shi, 583-8588, Japan
Hidaka-shi, 350-1298, Japan
Hirakata-shi, 573-1191, Japan
Kitaadachi-gun, 362-0806, Japan
Kurume-shi, 830-0011, Japan
Ota-shi, 373-8550, Japan
Sagamihara-shi, 252-0375, Japan
Shinjuku-ku, 162-8655, Japan
Sunto-gun, 411-8777, Japan
Takatsuki-shi, 569-8686, Japan
Ube-shi, 755-0241, Japan
Hwasun-gun, 58128, South Korea
Muang, 50200, Thailand